Top Story

Greater understanding of resistance mechanisms needed in basal cell carcinoma

April 21, 2015

NEW YORK — Hedgehog inhibitors have demonstrated high activity and durability in patients with advanced basal cell carcinoma, and they also possess a predictable toxicity profile, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

However, the impact of these agents on the natural history of metastatic disease remains unclear, and a greater understanding of resistance mechanisms is needed, Karl D. Lewis, MD, associate professor of medicine at the University of Colorado Denver’s cutaneous oncology program, said during a presentation.

Meeting News CoveragePerspective

Breast cancer incidence will increase by 50% by 2030

April 21, 2015
PHILADELPHIA — The total number of invasive and in-situ breast cancer cases in the United States likely will increase 50% by 2030, according to study results…
Meeting News CoveragePerspective

MPDL3280A shows promise in metastatic triple-negative breast cancer

April 20, 2015
PHILADELPHIA — The investigational immunotherapy MPDL3280A appeared well tolerated and demonstrated favorable efficacy in patients with metastatic triple-negative…
Stephen F Hodi Meeting News CoveragePerspective

Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma

April 20, 2015
PHILADELPHIA — Patients with treatment-naive advanced melanoma who underwent simultaneous treatment with ipilimumab and nivolumab demonstrated longer PFS and a…

Yale launches personalized therapy trial for metastatic melanoma

April 20, 2015
Yale University announced recently that it has begun a multicenter clinical trial to apply personalized medicine technology to the treatment of metastatic melanoma.The…
More News Headlines »
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »